Korean study confirms BESPONSA's safety in tough blood cancer
NCT ID NCT04307134
First seen Jan 04, 2026 · Last updated Jun 17, 2026 · Updated 25 times
Summary
This study monitored 108 Korean patients with relapsed or refractory B-cell acute lymphoblastic leukemia (ALL) who received BESPONSA. The main goal was to track side effects and see how well the drug worked in real-world settings. Results help confirm the drug's safety and effectiveness for this serious blood cancer.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEMATOLOGIC MALIGNANCY are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Pfizer
Seoul, South Korea
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.